International Clinical Trial: Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128381) titled 'Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)' on Aug. 13.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: M.D. Anderson Cancer Center

Condition: Myelofibrosis (MF) Chronic Myelomonocytic Leukemia (CMML)

Intervention: Drug: Axatilimab (SNDX-6352)

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: January...